The FDA this week expanded the use of dupilumab for children aged 6 months to 5 years with moderate-to-severe atopic dermatitis (AD) whose disease is not controlled with topical prescription therapies or when those treatments can't be used.
The FDA this week approved dupilumab (Dupixent) for children aged 6 months to 5 years with moderate-to-severe atopic dermatitis (AD).
The biologic, which came on the US market in 2017, is already approved for AD in patients aged 6 and older, as well as for a number of other type 2 inflammatory atopic diseases. Most patients with AD begin showing symptoms before the age of 5, according to a statement from Sanofi.
Sanofi and Regeneron said they are also pursuing approval for this age group with the European Medicines Agency and in additional countries.
Approval was based on phase 3 data evaluating dupilumab every 4 weeks (200 mg or 300 mg, based on body weight) plus low-potency topical corticosteroids (TCS) or TCS alone (placebo). The trial met the primary and all secondary endpoints.
At 16 weeks, patients who received dupilumab with TCS, compared with TCS alone, achieved the following results:
The safety profile of dupilumab observed through 16 weeks in this young population was similar to the safety profile in patients 6 years and older.
In addition, through 52 weeks, the long-term safety profile of dupilumab in children aged 6 months to 5 years was also similar to what was observed in the pivotal trial and consistent with what was seen in older patients with AD. Hand-foot-and-mouth disease and skin papilloma were, respectively, reported in 5% and 2% of patients on dupilumab aged 6 months to 5 years, and none of these cases led to treatment discontinuation.
Dupilumab is also approved for chronic rhinosinusitis with nasal polyposis AND ASTHMA. Last month, it became the first approved treatment for eosinophilic esophagitis, and the FDA recently accepted it for priority review for the treatment of prurigo nodularis.
Enhancing Outpatient Hemophilia Care May Improve Health Outcomes and Costs
May 18th 2024Prospective data from patients attending a rural practice in West Virginia between 2016 and 2023 show that a quality improvement program that followed guideline recommendations and was tailored to specific patient needs reduced preventable bleeds and lowered costs.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen